LPL Financial LLC Has $7.81 Million Stock Position in VanEck Biotech ETF (NASDAQ:BBH)

LPL Financial LLC lessened its stake in VanEck Biotech ETF (NASDAQ:BBH) by 2.6% in the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 48,159 shares of the company’s stock after selling 1,284 shares during the quarter. LPL Financial LLC owned about 1.55% of VanEck Biotech ETF worth $7,806,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors also recently modified their holdings of BBH. Cambridge Investment Research Advisors Inc. lifted its position in VanEck Biotech ETF by 1.9% during the 4th quarter. Cambridge Investment Research Advisors Inc. now owns 11,041 shares of the company’s stock valued at $1,764,000 after purchasing an additional 207 shares during the period. KWB Wealth acquired a new stake in VanEck Biotech ETF during the 4th quarter worth $216,000. Oppenheimer & Co. Inc. raised its position in shares of VanEck Biotech ETF by 11.6% during the 4th quarter. Oppenheimer & Co. Inc. now owns 2,685 shares of the company’s stock valued at $429,000 after acquiring an additional 280 shares during the last quarter. Rockefeller Capital Management L.P. raised its position in shares of VanEck Biotech ETF by 2.0% during the 4th quarter. Rockefeller Capital Management L.P. now owns 11,722 shares of the company’s stock valued at $1,871,000 after acquiring an additional 230 shares during the last quarter. Finally, Aspen Grove Capital LLC acquired a new position in shares of VanEck Biotech ETF in the 4th quarter valued at $1,574,000. 30.26% of the stock is owned by institutional investors.

VanEck Biotech ETF Stock Up 1.2 %

Shares of VanEck Biotech ETF stock opened at $164.68 on Wednesday. The business’s fifty day moving average is $159.10. VanEck Biotech ETF has a 12 month low of $136.76 and a 12 month high of $170.25.

VanEck Biotech ETF Company Profile

The BIOTECH HOLDING COMPANY DEPOSITARY RECEIPTS or HOLDRS TRUST was formed under the depositary trust agreement, among The Bank of New York, as trustee, Merrill Lynch, Pierce, Fenner & Smith Incorporated, other depositors and the owners of the Biotech HOLDRS. The trust currently holds shares of common stock or American depositary shares issued by a group of companies that were, at the time of the initial offering, generally considered to be involved in various segments of thebiotechnology industry.